Practical Insights in and Translational Aspects of Novel Immune Therapies in Multiple Myeloma

Are you a hematologist or oncologist treating patients with multiple myeloma?
If so, this workshop is for you!

This high-impact educational program, held in conjunction with the DGHO Annual Meeting, seeks to bridge the knowledge gap between CAR T administering centers and smaller community centers where the vast majority of oncology patients are treated, and raise awareness of novel immune based strategies including antibody drug conjugates, bispecific T cell engages, and CAR T therapies among healthcare professionals.

 Preliminary Agenda

The treatment of multiple myeloma has dramatically evolved in recent years with immune-based strategies resulting in a very high impact in the relapsed refractory setting. Several targets are being evaluated, but B cell maturation antigen (BCMA) has proven to result in high response rates with excellent duration of responses in a very heavily pretreated patient population. Given the plethora of different drug products in this space, including antibody-drug conjugates, T cell engagers and CAR T cells, this is a busy landscape and requires specific education around patient characteristics, treatment selection, and toxicity management to provide the best treatment options for our patients.

At the conclusion of this educational activity, you will be able to:
1. Understand the types of patients who should be considered for novel immune based strategies including bispecific T cell engagers and CAR T cell therapy.
2. Understand the differences between TCEs, antibody drug conjugates, and CAR T cell process and data for appropriate care of the patient prior to consideration for these therapies.
3. Understand toxicities and their management post-novel immune strategies.